Abstract

Colgate-Palmolive will report fiscal Q2 2026 results on July 31, 2026, Pre-MKt; this preview outlines market expectations for revenue, gross margin, net profit or margin, and adjusted EPS alongside business segment dynamics and analyst views.

Market Forecast

Consensus points to revenue of 5.36 billion US dollars for the current quarter, implying 6.54% year-over-year growth, with estimated EBIT of 1.10 billion US dollars, forecast to grow 2.98% year over year; the street projects adjusted EPS around 0.95, up 5.67% year over year. Margin expectations are for stable-to-slightly higher profitability versus last year, with gross margin guided by recent levels and net margin inferred in the low-teens range; forecasts imply incremental mix tailwinds and cost discipline underpinning adjusted EPS growth.

Management’s core narrative centers on steady momentum in Oral, Personal and Home Care and resilient Pet Nutrition, with product mix and pricing supporting revenue and EBIT expansion. The segment with the most promising incremental growth is Pet Nutrition, where Hill’s has continued to expand distribution and premium lines; investors look for sustained mid- to high-single-digit growth as a base case.

Last Quarter Review

The prior quarter delivered revenue of 5.32 billion US dollars, gross margin of 60.59%, GAAP net profit attributable to shareholders of 646.00 million US dollars with a net profit margin of 12.13%, and adjusted EPS of 0.97, which grew 6.59% year over year.

A key highlight was continued above-consensus delivery on revenue and EPS, supported by pricing and mix gains that offset input-cost inflation. Main business highlights showed Oral, Personal and Home Care contributing 4.13 billion US dollars and Pet Nutrition contributing 1.19 billion US dollars; combined, these categories sustained the company’s top-line expansion.

Current Quarter Outlook

Main business: Oral, Personal and Home Care

For the current quarter, Oral, Personal and Home Care remains the revenue anchor with a run-rate near 4.00 billion US dollars in recent results. Pricing carryover from prior increases, ongoing premiumization in toothpaste and manual power brushes, and targeted innovation in skin and home care are expected to keep organic growth in the mid-single digits. Promotional intensity in certain emerging markets may temper volume elasticity, but pricing plus mix should preserve the gross margin profile close to the last quarter’s level, aided by moderated input costs. FX remains a variable, but underlying demand indicators suggest stable consumption across key geographies. With EBIT leverage supported by advertising efficiency and procurement savings, segment margin should remain healthy, reinforcing adjusted EPS resilience even if volume growth is mixed.

Most promising business: Pet Nutrition (Hill’s)

Hill’s continues to represent the most attractive medium-term growth vector thanks to premium therapeutic and science-led diets. Distribution gains in specialty and e-commerce, along with veterinary channel engagement, support above-corporate-average growth. The current-quarter setup anticipates continued double-digit contribution from new formulas in metabolic, mobility, and gastrointestinal lines, complemented by capacity additions that reduce supply bottlenecks. While category growth has normalized from pandemic-era peaks, premium share capture and elasticity in prescription diets underpin a path to outperformance. Operating margin in Pet Nutrition benefits from favorable mix and disciplined trade spend, which may offset any incremental commodity or logistics noise. On a year-over-year basis, investors should expect Hill’s revenue to pace ahead of consolidated growth, sustaining the company’s blended margin and EPS cadence.

What could matter most for the stock this quarter

The stock’s near-term reaction is likely to hinge on gross margin trajectory and any commentary on pricing versus volume mix. If management signals that price-led growth is transitioning toward balanced volume recovery without sacrificing mix quality, investors may reward the shares for durability of growth. Furthermore, updates on Pet Nutrition capacity and innovation pipeline could be a swing factor for sentiment given its role as a growth premium within the portfolio. Lastly, FX disclosures and any incremental reinvestment in brand support will be parsed for implications to the back-half EPS progression; a stable cost environment and prudent A&P allocation should help maintain EPS guidance cadence.

Analyst Opinions

Most recent institutional commentary skews constructive, with a majority of analysts expecting Colgate-Palmolive to slightly exceed revenue and adjusted EPS forecasts on steady demand and improving mix; bullish views outnumber cautious takes by a meaningful margin. Several well-followed sell-side houses highlight supportive fundamentals: they point to sustained pricing power in Oral Care, incremental margin progress from supply-chain efficiencies, and continued share gains in Pet Nutrition as reasons for potential outperformance versus consensus. The prevailing opinion anticipates a clean print with limited downside risks outside of FX and category normalization, and sees room for upward revisions if margin expansion holds and Hill’s growth persists.